# BridgeBio to Participate in September Investor Conferences Canonical URL: https://biopharmsignal.com/news/BBIO/bridgebio-to-participate-in-september-investor-conferences-5daa2fc9 Ticker: BBIO Company: BridgeBio Source: BridgeBio Published: 2026-09-01 11:30 EST ## Summary BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage,... ## Article Body BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences: 21st Annual Wells Fargo Healthcare Conference, Boston, MA: Wednesday, September 9 at 1:30 pm EDT 2026 Cantor Global Healthcare Conference, New York, NY: Thursday, September 10 at 9:10 am EDT Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Tuesday, September 15 at 10:00 am EDT Bernstein Insights Healthcare Leaders and Disruptors 2026, New York, NY: Wednesday, September 23 at 9:40am EDT To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com . A replay of the webcasts will be available on the BridgeBio website for 90 days following the event. About BridgeBio Pharma, Inc. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn , X , Facebook , Instagram , YouTube , and TikTok . BridgeBio Media Contact: Kaitlyn Reilly, Director, Communications contact@bridgebio.com (650)-789-8220 BridgeBio Investor Contact: Kristen Kelleher, Director, Investor Relations ir@bridgebio.com ## Recent Company News - 2026-09-02 11:30 EST — [BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026](https://biopharmsignal.com/news/BBIO/bridgebio-to-present-new-data-on-the-impact-of-oral-infigratinib-on-medical-comp-d8290888) — Source: BridgeBio - 2026-09-01 11:30 EST — [BridgeBio to Participate in September Investor Conferences](https://biopharmsignal.com/news/BBIO/bridgebio-to-participate-in-september-investor-conferences-5daa2fc9) — Source: BridgeBio - 2026-08-31 19:44 EST — [BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans](https://biopharmsignal.com/news/BBIO/bridgebio-announces-agreement-with-u-s-government-to-improve-affordability-and-a-be1cdbf7) — Source: BridgeBio - 2026-08-30 14:00 EST — [Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM](https://biopharmsignal.com/news/BBIO/acoramidis-demonstrates-reversal-of-cardiac-structural-disease-progression-and-f-e882b920) — Source: BridgeBio - 2026-08-26 11:30 EST — [BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM](https://biopharmsignal.com/news/BBIO/bridgebio-announces-first-participant-dosed-in-ascend-attr-a-phase-3b-4-study-ev-898306f8) — Source: BridgeBio ## Related News - 2026-09-07 11:00 EST — ASND — [Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026](https://biopharmsignal.com/news/ASND/ascendis-to-share-its-latest-endocrinology-rare-disease-data-at-espe-2026-a501d9d2) - 2026-09-07 07:53 EST — TEVA — [Teva Announces Launch of Offering of Senior Notes](https://biopharmsignal.com/news/TEVA/teva-announces-launch-of-offering-of-senior-notes-94143bde) - 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553) - 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd) - 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)